Daily1d
FDA approves zolbetuximab with chemotherapy for treatment of Gastric and gastroesophageal cancer
U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...
WebMD1d
New First-in-Class Drug Approved for Advanced Stomach Cancer
The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
FDA approves Vyloy for advanced gastric or gastroesophageal junction cancer
The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...
Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
pharmaphorum4d
FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug
Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...
ARY News Live6d
VYLOY: Astellas’ gastric cancer therapy approved in US
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...
GlobalData on MSN4d
FDA approves Astellas’ VYLOY for gastric cancer treatment
Astellas Pharma has gained approval from the US Food and Drug Administration (FDA) for VYLOY (zolbetuximab-clzb), in ...
Cancer Therapy Advisor4d
Vyloy Approved for Gastric, GEJ Cancer
The FDA has approved Vyloy (zolbetuximab-clzb) in combination with chemotherapy to treat advanced gastric or GEJ cancer.
The Pharma Letter6d
FDA approves Astellas’ Vyloy
The US Food and Drug Administration has approved Vyloy (zolbetuximab-clzb), a claudin 18.2 (CLDN18.2)-directed cytolytic ...
SurvivorNet on MSN3d
New FDA Approval: Vyloy (Zolbetuximab) — A Promising Option for Advanced Gastric Cancer
Claudin 18.2 testing is a crucial step in determining whether Vyloy will be an effective treatment option for you patients with advanced gastric cancer.
BioWorld4d
Seaport sailing to the clinic with a $225M series B
Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...
BioSpace4d
Astellas’ First-in-Class, Claudin-Targeted Therapy Wins FDA Nod for Certain Gastric Cancers
The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only ...